TADC-derived RESISTIN promoted epithelial mesenchymal transformation (EMT) in lung cancer, which is a well-known mechanism underlying chemoresistance development by activating the Wolf–Hirschhorn syndrome candidate 1/Twist pathway [64]. Here, TWIST1 is linked to lung carcinoma.